Comparison
DSIP vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
80714-61-0
Molecular weight
848.81 g/mol
813.92 g/mol
Half-life
0.1 h
0.3 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
1
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1